Deep dives into drug development strategy, the five-choice cascade, and strategic clarity.
Drug development strategy is not a 30-slide deck. It is a single page of explicit choices about what you will and will not do to reach your goal. Most early-stage teams confuse plans with strategy. They are not the same thing.
Investors do not write checks for cool scientific ideas. They fund strategies with the potential to transform science into viable drug products. A translational mindset bridges the gap between your research and the capital needed to advance it.
Strategy is not goals and aspirations. It is not plans and experimental workflows. It is not your mission and vision statement. Strategy is about making explicit choices. This is the first in a five-part series on building a drug development strategy on a page.
The status quo is not where you will find drug innovation. It is where concepts lead to incremental changes in value. True strategy requires creating new market spaces, not optimizing your position in crowded ones.
Every successful drug development strategy rests on five integrated choices: indication selection, patient population definition, competitive positioning, evidence strategy, and regulatory pathway. Skip or misalign even one, and the entire strategy collapses.
Strategy Articles
Deep dives into drug development strategy, the five-choice cascade, and strategic clarity.
Target Product Profile
Everything you need to know about building and refining your TPP.
Execution & Team
Practical guidance on executing strategy and building aligned teams.
Regulatory Strategy
Regulatory pathways, FDA interactions, and approval strategies.